Study of Suramin in Subjects With Furosemide-Resistant AKI
- Registration Number
- NCT04496596
- Lead Sponsor
- Rediscovery Life Sciences
- Brief Summary
This is a prospective, double-blind, randomized, placebo-controlled study to assess the effects of suramin as a potential treatment option to prevent subjects with AKI from progressing to Kidney Disease Improving Global Outcomes (KDIGO) Stage III or dialysis dependent AKI.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 68
- At least 18 years of age at the time of signing the informed consent
- KDIGO Stage I AKI and a serum Cr increase ≥ 0.3 mg/dL within 48 hr or 1.5 to 1.9-times baseline (pre-FST) Cr levels within 48 hr (± 6 hr) prior to randomization OR KDIGO Stage II AKI and serum Cr increase 2.0 to 2.9-times baseline (pre-FST) Cr levels within 48 hr (± 6 hr) prior to randomization
- Fails to achieve a 200 mL increase in urine output within 2 hr following a 1.0 mg/kg bolus of furosemide (i.e., positive FST)
- If female of childbearing potential, must have a negative pregnancy test at Screening Is capable of providing informed consent as described in in this protocol.
- Receiving hemodialysis or peritoneal dialysis
- Prior renal transplant (other organ transplants are not excluded)
- Known baseline (pre-FST) estimated glomerular filtration rate (eGFR) ≤ 20 mL/min
- Evidence of hydronephrosis or obstructive uropathy confirmed by renal ultrasound (for subjects without a documented ultrasound, the
- Investigator will determine if a renal ultrasound is indicated, consistent with the standard of care (SOC)
- Hepatic encephalopathy, Child class C cirrhosis, and/or clinical suspicion of hepatorenal syndrome
- International normalized ratio (INR) ≤ 3.0, unless on stable long-term warfarin therapy within 2 weeks prior to randomization
- Known human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection
- Known coronavirus (COVID-19) infection
- White blood cell count (WBC) < 2,000/μL and/or platelet count < 30,000/μL at the time of Screening
- A sequential organ failure assessment (SOFA) score > 10 during Screening
- Subjects requiring 3 or more vasopressor agents of any combination to maintain a mean arterial pressure > 65 mm Hg
- Unwilling to participate in follow-up phone surveys up to 180 days post-treatment
- Are enrolled in another interventional research study or have participated in another interventional study within 14 days of Screening.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Suramin Suramin - Placebo Placebo -
- Primary Outcome Measures
Name Time Method To evaluate and compare the efficacy of a single 3.0 mg/kg infusion of suramin versus placebo in subjects with diuretic unresponsive AKI 7 days The difference between the effect of a 3.0 mg/kg infusion of suramin versus placebo will be based on meeting 2 or more of the composite event endpoints of: peak serum creatinine (Cr) of 6 mg/dL or above from investigational product (IP) infusion through Day or progression to KDIGO Stage III within 72 hours (hr) from IP infusion or death or dialysis from IP infusion through Day 7.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (12)
Ronald Reagan UCLA Medical Center
🇺🇸Los Angeles, California, United States
Emory University School of Medicine
🇺🇸Atlanta, Georgia, United States
Baylor Scott and White Research Institute - Dallas Clinical Trials Office
🇺🇸Dallas, Texas, United States
University of Arkansas Medical Sciences (UAMS)
🇺🇸Little Rock, Arkansas, United States
California Institute of Renal Research
🇺🇸La Mesa, California, United States
University of Kentucky
🇺🇸Lexington, Kentucky, United States
Emory Johns Creek Hospital
🇺🇸Johns Creek, Georgia, United States
University of Missouri - Dept. of Surgery
🇺🇸Columbia, Missouri, United States
University of New Mexico Health Science Center
🇺🇸Albuquerque, New Mexico, United States
New York-Presbyterian Medical Center of Queens
🇺🇸Flushing, New York, United States
Southeast Renal Research Institute
🇺🇸Chattanooga, Tennessee, United States
Wake Forest Baptist Medical Center
🇺🇸Winston-Salem, North Carolina, United States